A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

Pharmacodynamic- Part 1A & Part 2A (dose escalation) and Part B (dose expansion)

To assess immunomodulatory biomarker PD-L1 at baseline and on treatment as a single agent and in combination with other anti-cancer agents as specified in each respective module

Time frame: Measured with baseline and On-treatment biopsy. On-treatment biopsy is planned during Cycle 2 during Cycle 2 (each cycle is 28 days or 21 days depending on Module/dosing schedule)

Immunogenicity- Part 1A & 2A (dose escalation) and Part 2B (dose expansion)

To assess the incidence of anti-drug antibodies (ADA) against AZD6750 in serum and in combination with other anti-cancer agents as specified in each respective module

Time frame: Measured from pre-infusion on Cycle 1 up to Day 28 post last dose. Each cycle is 28 days or 21 days depending on Module/dosing schedule).

Efficacy (Part 1A and 2A)

To assess the preliminary anti-tumor activity of AZD6750 alone and in combination with other anti-cancer agents.

Time frame: Measured every 6 weeks for 48 weeks and every 12 weeks thereafter thereafter from first dose until disease progression or death in the absence of disease progression (approximately 2 years)

PK Maximum plasma concentration (Cmax)- Part 1A and Part 2A (dose escalation) and Part 2B (dose expansion)

To assess the plasma concentration of AZD6750 as a single agent and in combination with other anti-cancer agents as specified in each respective module. Each cycle is 28 days or 21 days depending on Module/dosing schedule)

Time frame: Measured from pre-infusion on Cycle 1 up to Day 28 post last dose on predefined intervals

PK Area Under Curve (AUC)- Part 1A and Part 2A (dose escalation) and Part 2B (dose expansion)

To assess the Area Under Curve (AUC) of AZD6750 as a single agent and in combination with other anti-cancer agents as specified in each respective module. Each cycle is 28 days or 21 days depending on Module/dosing schedule.

Time frame: Measured from pre-infusion on Cycle 1 up to Day 28 post last dose on predefined intervals

PK Time to maximum plasma concentration (tmax)- Part 1A and Part 2A (dose escalation) and Part 2B (dose expansion)

To assess the time to maximum plasma concentration of AZD6750 as a single agent and in combination with other anti-cancer agents as specified in each respective module. Each cycle is 28 days or 21 days depending on Module/dosing schedule.

Time frame: Measured from pre-infusion on Cycle 1 up to Day 28 post last dose on predefined intervals

PK Clearance- Part 1A and Part 2A (dose escalation) and Part 2B (dose expansion)

To assess the clearance of AZD6750 as a single agent and in combination with other anti-cancer agents as specified in each respective module. Each cycle is 28 days or 21 days depending on Module/dosing schedule.

Time frame: Measured from pre-infusion on Cycle 1 up to Day 28 post last dose on predefined intervals

PK Half-life- Part 1A and Part 2A (dose escalation) and Part 2B (dose expansion)

To assess the PK half-time of AZD6750 as a single agent and in combination with other anti-cancer agents as specified in each respective module. Each cycle is 28 days or 21 depending on Module/dosing schedule.

Time frame: Measured from pre-infusion on Cycle 1 up to Day 28 post last dose on predefined intervals

PK Minimum observed concentration (Cmin)- Part 1A and Part 2A (dose escalation) and Part 2B (dose expansion)

To assess the minimum observed concentration (Cmin) of AZD6750 as a single agent and in combination with other anti-cancer agents as specified in each respective module. Each cycle is 28 days or 21 days depending on Module/dosing schedule.

Time frame: Measured from pre-infusion on Cycle 1 up to Day 28 post last dose on predefined intervals